The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was established to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.
AMCP last week gathered a group of diverse health care stakeholders to discuss the challenges and opportunities of ensuring patient access to a category of emerging therapies known as “digital therapeutics,” which have the potential to treat a wide range of diseases and medical conditions.
AMCP and AMCP Foundation have set forth a four-part research agenda that identifies and prioritizes critical evidentiary gaps in managed care pharmacy.
Partnership Forum: Participants discussed how digital therapeutics with web and designed based applications are emerging as a means to treat conditions by engaging people to improve health and wellness.
A retrospective claims analysis in JMCP found that patients who received an outpatient opioid prescription following surgery had significantly increased health care utilization and costs for the following year.
AMCP CEO Blog: AMCP’s roughly 8,000 members work diligently every day to improve patient care through the optimized use of medicines. As an organization, we also take a leading role in developing improvements to the overall delivery of care, which is no easy task given the size and complexity of our health care system.